Research
Hormonal
Activation of the NLRP3 inflammasome in macrophages leads to the secretion of IL-1β and IL-18, which impair insulin signaling and contribute to beta-cell apoptosis in Type 2 Diabetes.
Chronic inflammation in fat tissue activates specific immune pathways (NLRP3 inflammasome) that release harmful cytokines (IL-1β). These cytokines damage insulin signaling and beta-cells. Addressing inflammation may help protect these cells.
StrongSupportsHIGH confidence
Once activated, NLRP3 interacts with procaspase-1 through an adaptive protein forming the NLRP3 inflammasome... This results in the processing and activation of caspase-1, which mediates the maturation and secretion of IL-1β and IL-18 by macrophages.
Why this rating
Supported by genetic ablation studies (NLRP3-/-) and clinical observations.
Source
Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes
Federica Zatterale et al. · Frontiers in Physiology · 2020
DOI 10.3389/fphys.2019.01607
narrative_reviewCited 1,092×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Chronic low-grade inflammation in adipose tissue, driven by M1 macrophage infiltration and pro-inflammatory cytokine secretion (TNF-α, IL-1β, IL-6), directly causes insulin resistance and contributes to the pathogenesis of Type 2 Diabetes.Strong
- Weight loss of up to 16% of original body weight is sufficient to improve beta-cell function and insulin sensitivity in adipose tissue, liver, and skeletal muscle by correcting dysregulated gene expression related to lipid and oxidative stress.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →